Search

Your search keyword '"Solomon, Scott"' showing total 6,859 results
Start Over Author "Solomon, Scott"
6,859 results on '"Solomon, Scott"'

153. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial

Author

Inzucchi, Silvio E, Claggett, Brian L, Vaduganathan, Muthiah, Desai, Akshay S, Jhund, Pardeep S, de Boer, Rudolf A, Hernandez, Adrian F, Kosiborod, Mikhail N, Lam, Carolyn S P, Martinez, Felipe, Shah, Sanjiv J, Verma, Subodh, Han, Yaling, Kerr Saraiva, Jose F, Bengtsson, Olof, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J V, and Solomon, Scott D

Published
2022
Full Text
View/download PDF

154. Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel

Author

Psotka, Mitchell A., Abraham, William T., Fiuzat, Mona, Filippatos, Gerasimos, Lindenfeld, JoAnn, Ahmad, Tariq, Felker, G. Michael, Jacob, Richard, Kitzman, Dalane W., Leifer, Eric S., Lewis, Eldrin F., Mentz, Robert J., Nkulikiyinka, Richard, Ni, Wei, Schaber, Daniel E., Sharma, Abhinav, Solomon, Scott D., Stockbridge, Norman, Teerlink, John R., Unger, Ellis F., Whellan, David J., Wittes, Janet, Anker, Stefan D., and O’Connor, Christopher M.

Published
2022
Full Text
View/download PDF

155. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Author

Myhre, Peder L., Vaduganathan, Muthiah, Claggett, Brian L., Miao, Zi Michael, Jhund, Pardeep S., de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., Desai, Akshay S., Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.

Published
2022
Full Text
View/download PDF

158. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction

Author

Butt, Jawad H., Kondo, Toru, Jhund, Pardeep S., Comin-Colet, Josep, de Boer, Rudolf A., Desai, Akshai S., Hernandez, Adrian F., Inzucchi, Silvio E., Janssens, Stefan P., Kosiborod, Mikhail N., Lam, Carolyn S.P., Langkilde, Anna Maria, Lindholm, Daniel, Martinez, Felipe, Petersson, Magnus, Shah, Sanjiv J., Thierer, Jorge, Vaduganathan, Muthiah, Verma, Subodh, Wilderäng, Ulrica, Claggett, Brian L., Solomon, Scott D., and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

161. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction

Author

Cunningham, Jonathan W., Vaduganathan, Muthiah, Claggett, Brian L., Kulac, Ian J., Desai, Akshay S., Jhund, Pardeep S., de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., McGrath, Martina M., O’Meara, Eileen, Wilderäng, Ulrica, Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.

Published
2022
Full Text
View/download PDF

164. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial

Author

Kondo, Toru, Jering, Karola S., Borleffs, C. Jan Willem, de Boer, Rudolf A., Claggett, Brian L., Desai, Akshay S., Dobreanu, Dan, Inzucchi, Silvio E., Hernandez, Adrian F., Janssens, Stefan P., Jhund, Pardeep, Kosiborod, Mikhail N., Lam, Carolyn S.P., Langkilde, Anna Maria, Martinez, Felipe A., Petersson, Magnus, Vinh, Pham Nguyen, Vaduganathan, Muthiah, Solomon, Scott D., and McMurray, John J.V.

Published
2023
Full Text
View/download PDF

165. A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study

Author

Johansen, Niklas Dyrby, Vaduganathan, Muthiah, Zahir, Deewa, Fiuzat, Mona, DeFilippis, Ersilia M., Januzzi, James L., Butler, Javed, O’Connor, Christopher M., Abraham, William T., Psotka, Mitchell A., McMurray, John J.V., Dewan, Pooja, Claggett, Brian L., Solomon, Scott D., Modin, Daniel, Butt, Jawad H., Jensen, Jens Ulrik Stæhr, Schou, Morten, Torp-Pedersen, Christian, Køber, Lars, Gislason, Gunnar H., and Biering-Sørensen, Tor

Published
2023
Full Text
View/download PDF

166. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Author

Bolaños-Meade, Javier, Reshef, Ran, Fraser, Raphael, Fei, Mingwei, Abhyankar, Sunil, Al-Kadhimi, Zaid, Alousi, Amin M, Antin, Joseph H, Arai, Sally, Bickett, Kate, Chen, Yi-Bin, Damon, Lloyd E, Efebera, Yvonne A, Geller, Nancy L, Giralt, Sergio A, Hari, Parameswaran, Holtan, Shernan G, Horowitz, Mary M, Jacobsohn, David A, Jones, Richard J, Liesveld, Jane L, Logan, Brent R, MacMillan, Margaret L, Mielcarek, Marco, Noel, Pierre, Pidala, Joseph, Porter, David L, Pusic, Iskra, Sobecks, Ronald, Solomon, Scott R, Weisdorf, Daniel J, Wu, Juan, Pasquini, Marcelo C, and Koreth, John

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Trials and Supportive Activities, Hematology, Transplantation, Cancer, Rare Diseases, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Bortezomib, Cyclophosphamide, Drug Interactions, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Male, Maraviroc, Methotrexate, Middle Aged, Mycophenolic Acid, Tacrolimus, Transplantation Conditioning, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

BackgroundPrevention of graft-versus-host disease (GvHD) without malignant relapse is the overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate regimens using either maraviroc, bortezomib, or post-transplantation cyclophosphamide for GvHD prophylaxis compared with controls receiving the combination of tacrolimus and methotrexate using a novel composite primary endpoint to identify the most promising intervention to be further tested in a phase 3 trial.MethodsIn this prospective multicentre phase 2 trial, adult patients aged 18-75 years who received reduced-intensity conditioning HCT were randomly assigned (1:1:1) by random block sizes to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide (cyclophosphamide 50 mg/kg on days 3 and 4, followed by tacrolimus starting on day 5 and mycophenolate mofetil starting on day 5 at 15 mg/kg three times daily not to exceed 1 g from day 5 to day 35); tacrolimus, methotrexate, and bortezomib (bortezomib 1·3 mg/m2 intravenously on days 1, 4, and 7 after HCT); or tacrolimus, methotrexate, and maraviroc (maraviroc 300 mg orally twice daily from day -3 to day 30 after HCT). Methotrexate was administered as a 15 mg/m2 intravenous bolus on day 1 and 10 mg/m2 intravenous bolus on days 3, 6, and 11 after HCT; tacrolimus was given intravenously at a dose of 0·05 mg/kg twice daily (or oral equivalent) starting on day -3 (except the post-transplantation cyclophosphamide, as indicated), with a target level of 5-15 ng/mL. Tacrolimus was continued at least until day 90 and was tapered off by day 180. Each study group was compared separately to a contemporary non-randomised prospective cohort of patients (control group) who fulfilled the same eligibility criteria as the trial, but who were treated with tacrolimus and methotrexate at centres not participating in the trial. The primary endpoint (GvHD-free, relapse-free survival [GRFS]) was defined as the time from HCT to onset of grade 3-4 acute GvHD, chronic GvHD requiring systemic immunosuppression, disease relapse, or death. The study was analysed by modified intention to treat. The study is closed to accrual and this is the planned analysis. This trial is registered with ClinicalTrials.gov, number NCT02208037.FindingsBetween Nov 17, 2014, and May 18, 2016, 273 patients from 31 US centres were randomly assigned to the three study arms: 89 to tacrolimus, methotrexate, and bortezomib; 92 to tacrolimus, methotrexate, and maraviroc; 92 to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; and six were excluded. Between Aug 1, 2014, and Sept 14, 2016, 224 controls received tacrolimus and methotrexate. Controls were generally well matched except for more frequent comorbidities than the intervention groups and a different distribution of types of conditioning regimens used. Compared with controls, the hazard ratio for GRFS was 0·72 (90% CI 0·54-0·94; p=0·044) for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide, 0·98 (0·76-1·27; p=0·92) for tacrolimus, methotrexate, and bortezomib, and 1·10 (0·86-1·41; p=0·49) for tacrolimus, methotrexate, and maraviroc. 238 patients experienced grade 3 or 4 toxicities: 12 (13%) had grade 3 and 67 (73%) grade 4 events with tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; ten (11%) had grade 3 and 68 (76%) had grade 4 events with tacrolimus, methotrexate, and bortezomib; and 18 (20%) had grade 3 and 63 (68%) had grade 4 events with tacrolimus, methotrexate, and maraviroc. The most common toxicities were haematological (77 [84%] for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; 73 [82%] for tacrolimus, methotrexate, and bortezomib; and 78 [85%] for tacrolimus, methotrexate, and maraviroc) and cardiac (43 [47%], 44 [49%], and 43 [47%], respectively).InterpretationTacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide was the most promising intervention, yielding the best GRFS; this regimen is thus being prospectively compared with tacrolimus and methotrexate in a phase 3 randomised trial.FundingUS National Health, Lung, and Blood Institute; National Cancer Institute; National Institute of Allergy and Infectious Disease; and Millennium Pharmaceuticals.

Published
2019

167. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction

Author

Butt, Jawad H., Dewan, Pooja, Jhund, Pardeep S., Anand, Inder S., Atar, Dan, Ge, Junbo, Desai, Akshay S., Echeverria, Luis E., Køber, Lars, Lam, Carolyn S.P., Maggioni, Aldo P., Martinez, Felipe, Packer, Milton, Rouleau, Jean L., Sim, David, Van Veldhuisen, Dirk J., Vrtovec, Bojan, Zannad, Faiez, Zile, Michael R., Gong, Jianjian, Lefkowitz, Martin P., Rizkala, Adel R., Solomon, Scott D., and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

171. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF

Author

Butt, Jawad H., Dewan, Pooja, DeFilippis, Ersilia M., Biering-Sørensen, Tor, Docherty, Kieran F., Jhund, Pardeep S., Kosiborod, Mikhail N., Martinez, Felipe A., Bengtsson, Olof, Johansen, Niklas Dyrby, Langkilde, Anna Maria, Sjöstrand, Mikaela, Vaduganathan, Muthiah, Solomon, Scott D., Sabatine, Marc S., Køber, Lars, Fiuzat, Mona, and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

172. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Author

Sehgal, Alison, Hoda, Daanish, Riedell, Peter A, Ghosh, Nilanjan, Hamadani, Mehdi, Hildebrandt, Gerhard C, Godwin, John E, Reagan, Patrick M, Wagner-Johnston, Nina, Essell, James, Nath, Rajneesh, Solomon, Scott R, Champion, Rebecca, Licitra, Edward, Fanning, Suzanne, Gupta, Neel, Dubowy, Ronald, D'Andrea, Aleco, Wang, Lei, Ogasawara, Ken, Thorpe, Jerill, and Gordon, Leo I

Published
2022
Full Text
View/download PDF

175. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

Author

Yeoh, Su Ern, Docherty, Kieran F., Campbell, Ross T., Jhund, Pardeep S., Hammarstedt, Ann, Heerspink, Hiddo J.L., Jarolim, Petr, Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Solomon, Scott D., Sjöstrand, Mikaela, Bengtsson, Olof, Greasley, Peter J., Sattar, Naveed, Welsh, Paul, Sabatine, Marc S., Morrow, David A., and McMurray, John J.V.

Published
2023
Full Text
View/download PDF

176. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Author

Kamdar, Manali, Solomon, Scott R, Arnason, Jon, Johnston, Patrick B, Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Maloney, David G, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Stepan, Lara, Ogasawara, Ken, Mack, Timothy, and Abramson, Jeremy S

Published
2022
Full Text
View/download PDF

181. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure

Author

Vaduganathan, Muthiah, Greene, Stephen J., Zhang, Shuaiqi, Solomon, Nicole, Chiswell, Karen, Devore, Adam D., Butler, javed, Heidenreich, Paul A., Huang, Joanna C., Kittleson, Michelle M., Joynt Maddox, Karen E., Mcdermott, James J., Owens, Anjali Tiku, Peterson, Pamela N., Solomon, Scott D., Vardeny, Orly, Yancy, Clyde W., and Fonarow, Gregg C.

Published
2022
Full Text
View/download PDF

182. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

Author

Docherty, Kieran F., Anand, Inder S., Chiang, Chern-En, Chopra, Vijay K., Desai, Akshay S., Kitakaze, Masafumi, Verma, Subodh, Vinh, Pham N., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Langkilde, Anna Maria, Jhund, Pardeep S., and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

184. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

Author

Wechalekar, Ashutosh, Antoni, Gunnar, Al Azzam, Wasfi, Bergström, Mats, Biswas, Swethajit, Chen, Chao, Cheriyan, Joseph, Cleveland, Matthew, Cookson, Louise, Galette, Paul, Janiczek, Robert L., Kwong, Raymond Y., Lukas, Mary Ann, Millns, Helen, Richards, Duncan, Schneider, Ian, Solomon, Scott D., Sörensen, Jens, Storey, James, Thompson, Douglas, van Dongen, Guus, Vugts, Danielle J., Wall, Anders, Wikström, Gerhard, and Falk, Rodney H.

Published
2022
Full Text
View/download PDF

185. Feasibility of randomizing Danish citizens aged 65–79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial

Author

Johansen, Niklas Dyrby, Modin, Daniel, Nealon, Joshua, Samson, Sandrine, Salamand, Camille, Larsen, Carsten Schade, Claggett, Brian L., Solomon, Scott D., Landray, Martin J., Gislason, Gunnar H., Køber, Lars, Jensen, Jens Ulrik Stæhr, Sivapalan, Pradeesh, Vestergaard, Lasse Skafte, Valentiner-Branth, Palle, Krause, Tyra Grove, and Biering-Sørensen, Tor

Published
2022
Full Text
View/download PDF

189. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

Author

Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Chung, Eugene, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean-Christophe, Fail, Peter, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, Hass, Moritz, Hausleiter, Jorg, Hayward, Christopher, Hickey, Gavin, Hummel, Scott, Hussain, Imad, Isnard, Richard, Izumi, Chisato, Jondeau, Guillaume, Juneman, Elizabeth, Kinugawa, Koichiro, Kipperman, Robert, Krakowiak, Bartek, Krim, Selim, Larned, Joshua, Lewis, Gregory, Lipsic, Erik, Magalski, Anthony, Mazimba, Sula, Mazurek, Jeremy, McGrady, Michele, Mckenzie, Scott, Mehta, Shamir, Mignone, John, Morsli, Hakim, Nair, Ajith, Noel, Thomas, Orford, James, Parikh, Kishan, Patterson, Tiffany, Penicka, Martin, Petrie, Mark, Pieske, Burkert, Post, Martijn, Raake, Philip, Romero, Alicia, Ryan, John, Saito, Yoshihiko, Sakamoto, Takafumi, Sakata, Yasushi, Samara, Michael, Satya, Kumar, Sindone, Andrew, Starling, Randall, Trochu, Jean-Noël, Upadhya, Bharathi, van der Heyden, Jan, van Empel, Vanessa, Varma, Amit, Vest, Amanda, Wengenmayer, Tobias, Westenfeld, Ralf, Westermann, Dirk, Yamamoto, Kazuhiro, Zirlik, Andreas, Shah, Sanjiv J, Borlaug, Barry A, Chung, Eugene S, Cutlip, Donald E, Debonnaire, Philippe, Fail, Peter S, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M, Litwin, Sheldon E, Lurz, Philipp, Massaro, Joseph M, Mohan, Rajeev C, Ricciardi, Mark J, Solomon, Scott D, Sverdlov, Aaron L, Swarup, Vijendra, van Veldhuisen, Dirk J, Winkler, Sebastian, and Leon, Martin B

Published
2022
Full Text
View/download PDF

190. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Author

Fuchs, Ephraim J., McCurdy, Shannon R., Solomon, Scott R., Wang, Tao, Herr, Megan R., Modi, Dipenkumar, Grunwald, Michael R., Nishihori, Taiga, Kuxhausen, Michelle, Fingerson, Stephanie, McKallor, Caroline, Bashey, Asad, Kasamon, Yvette L., Bolon, Yung-Tsi, Saad, Ayman, McGuirk, Joseph, Paczesny, Sophie, Gadalla, Shahinaz M., Marsh, Steven G.E., Shaw, Bronwen E., Spellman, Stephen R., Lee, Stephanie J., and Petersdorf, Effie W.

Published
2022
Full Text
View/download PDF

191. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial

Author

Solomon, Scott D., Vaduganathan, Muthiah, Claggett, Brian L., de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., Belohlavek, Jan, Chiang, Chern-En, Willem Borleffs, C. Jan, Comin-Colet, Josep, Dobreanu, Dan, Drozdz, Jaroslaw, Fang, James C., Alcocer Gamba, Marco Antonio, Al Habeeb, Waleed, Han, Yaling, Cabrera Honorio, Jose Walter, Janssens, Stefan P., Katova, Tsvetana, Kitakaze, Masafumi, Merkely, Bela, O’Meara, Eileen, Kerr Saraiva, Jose Francisco, Tereschenko, Sergey N., Thierer, Jorge, Vardeny, Orly, Verma, Subodh, Vinh, Pham Nguyen, Wilderäng, Ulrica, Zaozerska, Natalia, Lindholm, Daniel, Petersson, Magnus, and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

197. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

Author

Rossing, Peter, Inzucchi, Silvio E, Vart, Priya, Jongs, Niels, Docherty, Kieran F, Jhund, Pardeep S, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Solomon, Scott D, DeMets, David L, Bengtsson, Olof, Lindberg, Magnus, Langkilde, Anna Maria, Sjöstrand, Mikaela, Stefansson, Bergur V, Karlsson, Cecilia, Chertow, Glenn M, Hou, Fan Fan, Correa-Rotter, Ricardo, Toto, Robert D, Wheeler, David C, McMurray, John J V, and Heerspink, Hiddo J L

Published
2022
Full Text
View/download PDF

198. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

Author

Docherty, Kieran F., Ogunniyi, Modele O., Anand, Inder S., Desai, Akshay S., Diez, Mirta, Howlett, Jonathan G., Nicolau, Jose C., O’Meara, Eileen, Verma, Subodh, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Lindholm, Daniel, Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Langkilde, Anna Maria, Jhund, Pardeep S., and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

200. Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.

Author

Ostrominski, John W, Solomon, Scott D, and Vaduganathan, Muthiah

Subjects
HEART failure, GLUCAGON-like peptide-1 receptor, MAJOR adverse cardiovascular events, WEIGHT loss, LEAN body mass, GLUCAGON-like peptide-1 agonists
Abstract

The article discusses the potential benefits and considerations of combining sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) as therapy for heart failure with preserved ejection fraction (HFpEF) in individuals with obesity. The authors highlight that these medications may provide complementary benefits by targeting various pathophysiological features of obesity-related HFpEF. They also discuss the need for further research to establish the safety and efficacy of GLP-1RAs and combination therapy in HF populations. Additionally, the article addresses issues such as cost, polypharmacy, regimen complexity, and the lack of data in certain subpopulations. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results